Serum sFas and sFasL Levels in Patients with Type 2 Diabetes Mellitus and Arterial Hypertension

Material and methods: Ninety four type 2 diabetic patients (54 males and 40 females), divided to 3 groups, are included in the study – 26 subjects with type 2 diabetes and treated hypertension, of mean age 51,27±8,45 years (Group 1), 38 subjects with type 2 diabetes and untreated hypertension, of mean age 51,11±12,89 years (Group 2) and a control group of 30 patients with type 2 diabetes without hypertension, of mean age 47,57±8,62 years.

 

Twenty four-hour ambulatory blood pressure monitoring (Oscar, SunTech Medical Instruments, USA) was used to measure arterial blood pressure.

 

Standard anthropometric measurements of weight, height and waist circumference were performed.

 

Serum sFas and sFasL levels were evaluated with ELISA (Quantikine, R&D Systems, Minneapolis, USA).

 

Results: No differences in serum sFas levels are found between the groups. Serum sFasL levels are decreased both in Group 1 (р=0,001) and Group 2 (р=0,026) as compared to the control group. No difference in sFasL is found between the two groups with hypertension. No correlation of sFas and sFasL levels with age, BMI and waist circumference is established.

 

Conclusions: Subjects with type 2 diabetes and hypertension present with lower serum levels of sFasL as compared to normotensive subjects with type 2 diabetes. The decrease of serum sFasL does not depend on taking antihypertensive therapy.

 

Hypertension does not affect significantly serum sFas levels in patients with type 2 diabetes mellutus.